Tag: Bluebird Bio acquisition
Challenges at FDA & bluebird Bio Sale: What You Need to Know
This morning, Praxis Precision Medicine announced that an independent data monitoring committee recommended discontinuing a Phase 3 study involving its experimental treatment for essential tremors. The analysis indicated that the drug was unlikely to...
Bluebird Bio Sold to Carlyle, SK Capital for Under $30M
Bluebird Bio, a once-promising biotech company, made headlines recently with its decision to sell itself and its portfolio of gene therapies to investment firms Carlyle and SK Capital for less than $30 million. This...
